Search Results
Feb 26, 2026, 17:31 ET Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight
Myeloid Leukemia (AML), relapsed or refractory Myelodysplastic Syndromes (MDS), and in locally advanced or metastatic cholangiocarcinoma.A Phase III study (NCT06127407) is now underway in adults (18+) with locally advanced or metastatic conventional chondrosarcoma carrying an IDH1 mutation. Eligible
More news about: DelveInsight Business Research, LLP
Feb 26, 2026, 16:30 ET Prologis to Participate in Industry Conferences
local economic and political climates and conditions; (ii) changes in global financial markets, interest rates and foreign currency exchange rates; (iii) increased or unanticipated competition for our properties; (iv) risks associated with acquisitions, dispositions and development of properties, including
More news about: Prologis, Inc.
Feb 26, 2026, 16:26 ET Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business
Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including
More news about: Ginkgo Bioworks
Feb 26, 2026, 16:15 ET MAIN STREET ANNOUNCES 2025 FOURTH QUARTER AND ANNUAL RESULTS
the Corporate Facility to decrease the interest rate, increase the total commitments to $1.145 billion and extend the maturity date to April 2030, (iii) issuing an aggregate principal amount of $350.0 million of the August 2028 Notes and (iv) fully prepaying $150.0 million of notes outstanding in September
More news about: Main Street Capital Corporation
Feb 26, 2026, 16:15 ET MSC INCOME FUND ANNOUNCES 2025 FOURTH QUARTER AND ANNUAL RESULTS
investment portfolio), (ii) reduce to 17.5% the subordinated incentive fee on income payable by the Fund, subject to a 50% / 50% catch-up feature, (iii) reduce to 17.5% and reset the incentive fee on cumulative net realized capital gains payable by the Fund and (iv) establish a cap on the amount of expenses
More news about: MSC Income Fund, Inc.
Feb 26, 2026, 16:15 ET American Healthcare REIT ("AHR") Announces Fourth Quarter 2025 and Full Year 2025 Results; Issues Full Year 2026 Guidance
an indicator of our operating performance, (ii) more relevant or accurate than GAAP cash flows from operations as an indicator of our liquidity or (iii) indicative of funds available to fund our cash needs, including our ability to make distributions to our stockholders. The method utilized to evaluate
More news about: American Healthcare REIT, Inc.
Feb 26, 2026, 16:05 ET DIAMOND HILL INVESTMENT GROUP, INC. REPORTS 2025 FINANCIAL RESULTS
non-renewal, or termination of investment advisory or administration agreements, including as a result of the pending merger or client consent requirements; (iii) risks related to, or the failure to consummate, the proposed acquisition of the Company by First Eagle Investment Management, LLC, including the failure
More news about: Diamond Hill Investment Group, Inc.
Feb 26, 2026, 16:05 ET DIAMONDROCK HOSPITALITY COMPANY REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
Company's option, (ii) a $500 million term loan maturing in January 2028, with two six-month extension options exercisable at the Company's option, (iii) a $300 million term loan maturing in January 2029, with two six-month extension options exercisable at the Company's option, and (iv) a $300 million
More news about: DiamondRock Hospitality Company
Feb 26, 2026, 16:03 ET BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
approximately 250 ongoing commercially sponsored CGT clinical trials in the U.S., representing a more than 70% market share. This includes over 30 Phase III trials, or nearly 80% of the late-stage CGT trials. Our CellSeal® vials and human platelet lysate ("hPL") products are used in over 35 clinical
More news about: BioLife Solutions, Inc.
Feb 26, 2026, 16:01 ET Curaleaf Reports Fourth Quarter and Full Year 2025 Results: Domestic and International Growth Accelerate with Gross Margin Expansion
additional insight into the Company's financial strength and underlying performance, (ii) align external reporting with how management evaluates results and (iii) facilitate comparisons with other issuers. These measures should not be considered in isolation from, or as a substitute for, U.S. GAAP results nor
More news about: Curaleaf Holdings, Inc.
Feb 26, 2026, 16:00 ET Smart Sand, Inc. Announces Fourth Quarter 2025 and Full Year 2025 Results
other results of operations based taxes; and (iii) interest expense. We define Adjusted EBITDA as EBITDA, plus: (i) gain or loss on sale of fixed assets or discontinued operations; (ii) integration and transition costs associated with specified transactions; (iii) equity compensation; (iv) acquisition and
More news about: Smart Sand, Inc.
Feb 26, 2026, 15:50 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Sale of Endeavor Group Holdings, Inc. Class A Common Stock of Class Action Lawsuit and Upcoming Deadlines - EDR
consideration without any collar or contingent value right and offering only a de minimis dividend to shareholders that they shared with themselves; and (iii) disseminating a misleading Information Statement on January 15, 2025 that spoke in present tense about "fairness" and "best interests" to unaffiliated
More news about: Pomerantz LLP
Feb 26, 2026, 15:17 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
$10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025.Then, on December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had failed to "achieve statistical significance against the primary endpoints of reduction in annualized clinical fracture rate
More news about: Pomerantz LLP
Feb 26, 2026, 15:01 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pinterest, Inc. - PINS
reallocating resources to AI-focused roles and teams that drive AI adoption and execution, (ii) prioritizing AI–powered products and capabilities, and (iii) accelerating the transformation of its sales and go-to-market approach." On this news, Pinterest's stock price fell $2.49 per share, or 9.61%,
More news about: Pomerantz LLP
Feb 26, 2026, 14:50 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Enphase Energy, Inc. and Certain Officers - ENPH
its ability to manage its channel inventory; (ii) Enphase overstated its ability to mitigate effects arising from the termination of the 25D Credit; (iii) accordingly, Enphase overstated its financial and operational prospects; and (iv) as a result, the Company's public statements were materially false
More news about: Pomerantz LLP
Feb 26, 2026, 14:50 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory
More news about: Pomerantz LLP
Feb 26, 2026, 14:50 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Beyond Meat, Inc. and Certain Officers - BYND
foregoing was likely to impair Beyond Meat's ability to timely file its periodic filings with the U.S. Securities and Exchange Commission ("SEC"); and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.The complaint alleges that
More news about: Pomerantz LLP
Feb 26, 2026, 14:50 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Plug Power Inc. and Certain Officers - PLUG
facilities necessary to receive those funds; (ii) as such, Plug Power was likely to pivot toward more modest projects with less commercial upside; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.On October 7, 2025, Plug Power issued
More news about: Pomerantz LLP
Feb 26, 2026, 14:50 ET Pomerantz Law Firm Announces the Filing of a Class Action Against CoreWeave, Inc. and Certain Officers - CRWV
that CoreWeave's reliance on a single third-party data center supplier presented for CoreWeave's ability to meet customer demand for its services; (iii) the foregoing was reasonably likely to have a material negative impact on the Company's revenue; (iv) as a result, the Company's public statements were
More news about: Pomerantz LLP
Feb 26, 2026, 14:50 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Lakeland Industries, Inc. and Certain Officers - LAKE
these businesses on Lakeland's financial results, as well as the overall strength and quality of Pacific Helmets' and Jolly's respective operations; (iii) Lakeland's business and financial results were significantly deteriorating because of, inter alia, tariff-related headwinds and timing, certification
More news about: Pomerantz LLP
Feb 26, 2026, 13:54 ET Dr. Marcus Coplin Releases Future Wellness 2026: Seven Frontiers Redefining Human Vitality White Paper
to the promotion of life itself? It is the shift from "doing wellness" to being well-designed individually, collectively, and systemically.III. The Seven Frontiers of 2026 Wellness LeadershipWhere Regenerative Science Meets Everyday Practice. The wellness landscape is no longer
More news about: Murrieta Hot Springs Resort
Feb 26, 2026, 11:09 ET The Cancer & Hematology Centers Expands Into Urology Specialty in Michigan
with an expanded reach beyond West Michigan, we offer patients across Michigan access to cutting-edge treatments and participation in phase I, II, and III clinical trials—all within a compassionate and caring environment. Our services include benign and malignant hematology programs, outpatient specialty
More news about: Cancer & Hematology Centers
Feb 26, 2026, 11:00 ET Forbes Names Mesirow Wealth Advisor Jennifer Rosenblum, CFA on 2026 Top Women Wealth Advisors Best-in-State List
passive currency risk management products $214.27 billion, (ii) non-fx overlay strategies such as equitization and beta overlays $1.09 billion, and (iii) alpha strategies $1.76 billion. In all such cases, AUM is calculated based on notional value of currency investments. Additionally, AUM for alpha strategies
More news about: Mesirow Financial Holdings, Inc.
Feb 26, 2026, 10:50 ET 212NYC and Marketecture Announce Media Partnership for Marketecture Live III: Consumers in Control
Advertising Club and Marketecture Media are pleased to announce that 212NYC has been confirmed as a Media Partner for Marketecture Live III: Consumers in Control, taking place on March 10-11, 2026. This partnership marks the launch of a broader strategic collaboration aimed at
More news about: 212NYC New York's Digital Advertising Club
Feb 26, 2026, 10:30 ET Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses
for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; and (iv) accordingly,
More news about: Robbins LLP